The pros and cons of genetic testing for breast and ovarian cancer risk

International Journal of Fertility and Women's Medicine

Volumn 44, Issue 3, 1999, Pages 139-145

  Frank, Thomas S ^a   Braverman, Andrea Mechanick ^b  

^a Myriad Genetic Laboratories   (United States)

^b Pennsylvania Reproductive Associates   (United States)

Author keywords

BRCA1; BRCA2; Breast; Cancer; Hereditary; Ovary; Psychology

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; DISEASE PREDISPOSITION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC DISORDER; GENETIC PREDISPOSITION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MULTIGENE FAMILY; OVARY CANCER; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOLOGY;

GENETICS AND REPRODUCTION;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, TUMOR SUPPRESSOR; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 0032776682     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Claus EB, Schildkraut JM, Thompson WD, et al: The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318-2324, 1996.
2. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676-689, 1998.
3. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [see comments]. N Engl J Med 336:1401-1408, 1997.
4. Easton DF, Ford D, Bishop DT, et al: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56: 265-271, 1995.
5. Whittemore AS, Gong G, Itnyre J: Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 60:496-504, 1997.
6. Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCA1 -mutation carriers. Lancet 343:692-695, 1994.
7. Verhoog LC, Brekelmans CTM, Seynaeve C, et al: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351:316-321, 1998.
8. Frank TS, Manley SA, Olopade OI, et al: Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425, 1998.
9. Robson M, Gilewski T, Haas B, et al: BRCA-associated breast cancer in young women. J Clin Oncol 16: 1642-1649, 1998.
10. Johannsson OT, Ranstam J, Borg A, et al: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16:397-404, 1998.
11. FitzGerald MG, MacDonald DJ, Krainer M, et al: Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334:143-149, 1996.
12. Abeliovich D, Kaduri L, Lerer I, et al: The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505-514, 1997.
13. Beller U, Halle D, Catane R, et al: High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol 67:123-126, 1997.
14. Couch FJ, DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer [see comments]. N Engl J Med 336:1409-1415, 1997.
15. Fearon ER: Human cancer syndromes: clues to the origin and nature of cancer. Science 278:1043-1050, 1997.
16. Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277: 997-1003, 1997.
17. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90: 1371-1388, 1998.
18. Study shows mastectomy prevents breast cancer in high-risk women. JAMA 277:1421-1422, 1997 [Abstract].
19. Lerman C, Narod S, Schulman K, et al: BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 275:1885-1892, 1996.
20. Berchuck A, Cirisano F, Lancaster JM, et al: Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 175: 738-746, 1996.
21. Ponder B: Genetic testing for cancer risk. Science 278:1050-1058, 1997.
22. Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339:424-428, 1998.
23. NIH Consensus Development Panel on Ovarian Cancer: Ovarian Cancer. Screening, treatment and follow-up. JAMA 273:491-497, 1995.
24. Rubin SC, Benjamin I, Behbakht K, et al: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1 [see comments]. N Engl J Med 335:1413-1416, 1996.
25. Cummings S, Olopade O: Predisposition testing for inherited breast cancer. Oncology 12:1227-1242, 1998.
26. Koenig BA, Greely HT, McConnell LM, et al: Genetic testing for BRCA1 and BRCA2: Recommendations of the Stanford program in genomics, ethics, and society. J Womens Health 7:531-545, 1998.
27. Quaid KA, Morris M: Reluctance to undergo predictive testing: the case of Huntington's disease. Am J Med Genet 45:41-45, 1993.
28. Bekker H, Modell M, Denniss G, et al: Uptake of cystic fibrosis testing in primary care: supply push or demand pull? Br Med J 306(6892-Jun 12):1584-1586 [comments-1558], 1993.
29. Tambor ES, Bernhardt BA, Chase GA, et al: Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Am J Hum Genet 55:626-637, 1994.
30. Evers-Kiebooms G, Swerts A, Cassiman JJ, et al: The motivation of at risk individuals and their partners in deciding for or against predictive testing for Huntigton's disease. Clin Genet 35:29-40, 1989.
31. Kessler S, Field T, Worth L, et al: Attitudes of persons at risk for Huntington's disease toward predictive testing. Am J Med Genet 26:259-270, 1987.
32. Craufurd D, Dodge A, Kurzin-Storrar L, et al: Uptake of presymptomatic predictive testing for Huntington's disease. Lancet 2:603-605, 1989.
33. Sleek S: How will genetic testing affect us emotionally? APA Monitor p. 35, October 1998.
34. Lerman C, Hughes C, Lemon SJ, et al: What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 16:1650-1654, 1998.
35. Schneider KA: Genetic counseling for BRCA1/ BRCA2 testing. Gen Testing 1:91-98, 1998.